GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-d-aspartate receptor modulator
- 1 December 2005
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 49 (7) , 1077-1087
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (F31 MH12761, R37 AG08796, R43-MH60572)
This publication has 65 references indexed in Scilit:
- A novel TNFα antagonizing peptide-Fc fusion protein designed based on CDRs of TNFα neutralizing monoclonal antibodyBiochemical and Biophysical Research Communications, 2004
- Trace eyeblink conditioning in the freely moving rat: Optimizing the conditioning parameters.Behavioral Neuroscience, 1999
- L‐687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotectiveBritish Journal of Pharmacology, 1998
- NMDA Receptor Heterogeneity During Postnatal Development of the Rat Brain: Differential Expression of the NR2A, NR2B, and NR2C Subunit ProteinsJournal of Neurochemistry, 1997
- Co-agonism in drug-receptor interaction: illustrated by the NMDA receptorsTrends in Pharmacological Sciences, 1996
- Antibody-structure-based design of pharmacological agentsTrends in Biotechnology, 1994
- Cloning, expression and modulation of a mouse NMDA receptor subunitFEBS Letters, 1992
- Glycine‐Like Modulation of N‐Methyl‐d‐Aspartate Receptors by a Monoclonal Antibody That Enhances Long‐Term PotentiationJournal of Neurochemistry, 1991
- Apparent desensitization of NMDA responses in xenopus oocytes involves calcium-dependent chloride currentNeuron, 1990
- Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coliNature, 1989